Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EVT 201 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| EVT 201 | DRUG | - |
Inclusion Criteria: * Diagnosis of primary insomnia according to DSM-IV * Over the last three months for at least 5 nights per week, must have a normal bedtime of between 9 pm and 1 am and a time in bed of at least 7 hours * A history of sleepiness, tiredness or unintentional napping during the day...
EVT 201 is an investigational small molecule being developed for sleep initiation and maintenance disorders, a class of conditions that includes insomnia. It is being studied in patients who have difficulty falling asleep or staying asleep. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
EVT 201 is being developed by Evotec SE, a biopharmaceutical company traded on the stock exchange under the ticker EVO. The company is conducting clinical trials to evaluate the drug's safety and efficacy for the treatment of sleep initiation and maintenance disorders.
EVT 201 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory agencies such as the FDA. The drug is being studied for its potential to treat sleep initiation and maintenance disorders, including insomnia.
EVT 201 has been studied in two completed Phase 2 clinical trials. The first trial, NCT00380003, enrolled 66 adults aged 21 and older to evaluate the drug's efficacy in treating insomnia. The second trial, NCT00401284, enrolled 135 elderly patients aged 65 and older to assess the drug's effects on daytime sleepiness.
EVT 201 is the primary name used for this investigational drug in clinical trials and development. No alternative names have been reported for this compound. It is a small molecule being developed by Evotec SE for the treatment of sleep initiation and maintenance disorders.